Skip to content

Comparison of two drugs for intubating during awake fiberoptic broncoscopy in oral carcinoma surgeries

A comparison between Fentanyl and Nalbuphine for intubating conditions during awake fiberoptic broncoscopy in oral carcinoma surgeries: A randomized comparative prospective study - Nil

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/04/065255
Enrollment
154
Registered
2024-04-05
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Department of Anaesthesiology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients included in the study should meet the following inclusion criteria- Age- 18-70 years of either gender ASA physical status -I or II Type of surgery- Oral carcinoma surgery Nature of surgery-Elective MP grade III &IV Type of anaesthesia- General Anaesthesia Patients giving written informed consent

Exclusion criteria

Exclusion criteria: Patient Refusal MP grade I &II ASA III &IV Allergy to drug Major cardiorespiratory disease Emergency surgeries Difficult mask ventilation Nasal mass Coagulation disorder Hepatic or renal disease Pregnant patients

Design outcomes

Primary

MeasureTime frame
To compare intubating conditions among two groups with intubation score Coughing and post intubation scoreTimepoint: 4 hrs

Secondary

MeasureTime frame
To compare haemodynamic parameters among two groups. To compare sedation (Ramsay sedation score) among two groups. Timepoint: 0 min to 2hrs

Countries

India

Contacts

Public ContactDr Aparna Shukla

King Georges Medical University Lucknow

draparnashukla@yahoo.com9918038878

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026